Replies to post #17963 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

...timeline we might expect in the IVIG and inflammation areas?

2020 timeline. However, FDA could move-up approval, if warranted.

Noted:
M254(hsIVIg), Shows up to 10x Enhanced Anti-Inflammatory Activity in Preclinical Autoimmune Models

has the potential to be a more potent, subcutaneous alternative to IVIg

Plan to initiate an IND-enabling toxicology study in 2017 and to initiate a clinical trial in 2018

http://files.shareholder.com/downloads/MNTA/5638182076x0x963952/B2EBC2CC-1278-410B-8091-A71F67A468A9/Momenta_Current_Corporate_Presentation_Nov2017.pdf